Summary The inhibitory effect of c-myb antisense oligodeoxynucleotides (ODNs) conjugated to folic acid (FA) on HL-60 cell proliferation was examined. Folic acid was covalently linked to a polylysine chain and purified by gel chromatography. Sterile FA-polylysine was complexed with c-myb sense and antisense. Exposure of HL-60 cells to the FA-polylysine-c-myb antisense ODN complex resulted in a down-regulation of c-myb expression and a greater inhibition of proliferation than that obtained using free ODNs. Moreover, FA-polylysine conjugate alone or complexed to c-myb sense ODN was not toxic to cells. The antigenic properties and uptake of the vitamin were not affected by the polylysine chain. These data suggest that this strategy is potentially useful for the selective delivery of anti-oncogene-targeted ODNs into cancer cells.
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Antisense oligodeoxynucleotides (ODNs) have proven useful for selective inhibition of gene expression (Holt et al., 1988; Szczylik et al, 1991) . However, their rate of cellular uptake appears to be quite slow, and consequently attempts have been made to enhance their stability and their delivery into cells. For instance, receptor-mediated endocytosis has been used to increase the uptake of synthetic ODNs and other foreign molecules such as proteins complexed to specific ligands (Wu & Wu, 1987 , 1988 Cotten et al., 1990; Leamon & Low, 1991; Citro et al., 1992; Manfredini et al., 1993) . Since the receptors for some growth factors, vitamins and hormones are overexpressed in rapidly dividing tumour cells (Rothemberg & Da Costa, 1971; Asok et al., 1981; Sclhub & Franklin, 1984; Lacey et al., 1989) , the ligands of these receptors can be exploited to selectively introduce therapeutic compounds into the cells. The use of modified ligands for specific cell-surface receptors as carriers of oncogene-targeted antisense ODNs represents a potentially useful therapy to be used alone or in combination with antineoplastic drugs.
We have previously reported that a c-myb antisensetransferrin-polylysine complex produces an enhanced uptake into HL-60 cells, resulting in an increased biological effect. Recently, we have also observed that a polylysine chain covalently linked to compounds such as insulin, folic acid, retinoic acid, oestrone and testosterone can be used for specific interactions with nucleic acids in physiological ionic conditions (G. Citro, unpublished observation). The presented study describes the efficacy of folic acid receptor-targeted c-myb antisense in the HL-60 cell line. The effect of the complexed phosphodiester (PO) ODNs was compared with that of phosphorothioate (PS) ODN antisense given alone.
With doses of 20 and 30 fig mlVl, we found that PS c-myb antisense actively inhibited the rate of the cell proliferation while free PO c-myb antisense had no effect. However, when free PO c-myb antisense ODNs were complexed to FApolylysine, their inhibitory effect on the cell proliferation was even greater than that obtained using the free PS oligos. Furthermore, whereas recent research has indicated there are some drawbacks to the use of PS oligos in systemic therapy (Stein & Cheng, 1993) , PO oligos might prove useful since their metabolites are similar to physiological compounds, resulting in less aspecific toxicity.
Materials and methods
Folic acid-polylysine and oligodeoxynucleotide conjugates Folic acid (FA) was dissolved in 20 mM sodium phosphate buffer at pH 4.5 and incubated with a 6-fold molar excess of Slots were incubated first with anti-FA monoclonal antibody (clone VP 52; mouse IgG2b; Sigma), then with goat anti-mouse horseradish peroxidase (HRP) conjugate, and developed using the HRP substrate 4-chloronaphthol. The polylysine not complexed to folic acid was used as a control to verify the absence of aspecific immunoreactivity.
Fluorescence microscopy To ensure the same amount of fluorescein (FITC) in both compounds used in cell treatments, FITC-polylysine (Sigma) was coupled to FA or left unconjugated as control.
HL-60 cells (106ml-') were incubated for different lengths of time (from 5 to 300 min) at 37°C with FITC-polylysinefolic acid conjugate (final concentration of folic acid 10-7 M). Cells were then washed five times with cold PBS, cytocentrifuged (Shandon) and fixed at 4°C in absolute acetone for 15 min. Cells were photographed through a Leitz microscope with a 40 x phase-contrast/fluorescence objective.
Formation of thefolic acid-polylysine-c-myb olygodeoxynucleotide complexes
Sterile FA-polylysine (30 ng pth') was mixed with various amounts of c-myb antisense or sense ODN in sterile aqueous solution. Complexes were allowed to form for 1 h at room temperature before being added to the cells.
Cells and culture conditions
Human promyelocytic leukaemia cells (HL-60) were grown in suspension in a humidified atmosphere of 95% (v/v) air and 5% (v/v) carbon dioxide at 37°C in RPMI-1640 and 10% heat-inactivated fetal calf serum supplemented with 102 tLg ml1 penicillin G, 102 gLg ml-' streptomycin and 120 ltg ml-' L-glutamine. The cells were grown to densities of 1 x 105 cells before harvesting (Collins et al., 1977; Koeffier, 1983) . For all the experiments, cells were cultured in 24 well Costar plates at an initial concentration of 1 x 104 in RPMI-1640 folate-deficient medium prepared according to Barton and Capdevila (1986) . Doses of 10 or 20 ig ml1' ODNs were added to cells, followed by two subsequent doses of 5 tLg at 24 and 48 h. The control cells were treated with the same doses of FA-polylysine conjugate (10-7 M) used in the oligo complex preparation.
Cell number and viability were determined using an electronic particle counter and trypan blue exclusion assay every 2 days.
c-myb mRNA levels in HL-60 cells Reverse transcription-polymerase chain reaction (RT-PCR) for detection of c-myb mRNA transcripts was carried out as previously described (Chomczynski & Sacchi, 1987; Venturelli et al., 1990) . A 3' ODN primer c-myb corresponding to nucleotides 2,466-2,487 and a 5' ODN primer c-myb corresponding to nucleotides 2,258-2,279 of the published cDNA sequence were utilised (Majello et al., 1986) . After 30 cycles, 10 l of amplified product was electrophoresed on a 4% agarose gel and then transferred to a nylon filter. Filters were prehybridised and then probed with a 32P-end-labelled oligonucleotide probe (Sambrook et al., 1989) corresponding to a 50 base c-myb oligomer sequence contained within the amplified region from nucleotides 2,351 to 2,400. As control, P-actin mRNA was amplified with ,-actin-specific primers and detected with a specific probe, as described by Nicolaides et al. (1991) . Hybridisation was detected by autoradiography.
Results

Purification of the folic acid-polylysine conjugate
The elution profile of the polylysine and FA mixed in the absence of the coupling agent is shown in Figure 1 (top). Two separated peaks were observed under physiological ionic conditions (100 mM phosphate buffer saline, pH 7.4). Fluoresceinated polylysine was recovered in fractions 4-8, while free folic acid was collected from fractions 23-35. The fluoresceinated polylysine-FA conjugate eluted in the excluded volume shows (Figure 1 , bottom) as a single sharp peak with a strong UV absorption at 287 nm. The conjugate rechromatographed at high ionic strength (2 M sodium chloride in PBS, pH 7.4) showed a similar elution profile, demonstrating that the compounds were covalently bound (data not shown). The average conjugation ratio of FApolylysine was 0.5. Immunodetection offolic acid in the conjugate As the specific MAb used was able to recognise both FA and its active metabolite, the conjugation of FA with polylysine chain did not alter the active site of the FA molecules. The specific MAb showed a dose-dependent reaction with the vitamin in the conjugate. Figure 2 shows the results of a slot blot assay (in duplicate) obtained using an increasing concen- (Figure 4 ). It is evident that ODN mixed with FA or alone migrated to the positive charged pole (Figure 4a and c) . On the other hand the negative charge of the ODN when complexed to the FA-polylysine conjugate was completely neutralised by the polylysine chains ( Figure  4b ).
Effect offolic acid-polylysine-oligodeoxynucleotide complex on the proliferation of HL-60 cells HL-60 cell proliferation is inhibited by exposure to c-myb antisense ODNs in excess of 10 jaM (Anfossi et al., 1989; Ferrari et al., 1990; Nicolaides et al., 1991) . In agreement with our previous results (Citro et al., 1992) , 20 and 30 tsg ml1 l doses of free phosphodiester (PO) c-myb antisense ODNs had no effect on the HL-60 cell proliferation. Indeed, after 6 days the cell number of all the treated cells was similar to that of the control: PO sense 201sg ml-' = 540 + 7 x 10 2; PO sense 30 ljg ml-' = 515 ± 15 x 102; PO antisense 20 ig ml-' = 490 ± 10 x 102; PO antisense 30 ig ml-' = 495 ± 20 x 102; control = 520 ± 10 x 102. However, doses of 20 and 30 tg ml1' phosphorothioate (PS) c-myb antisense ODNs clearly impaired HL-60 cell proliferation (Figure 5a ). The same doses of ODNs phosphodiester complexed to the FA-polylysine conjugate induced a dose-dependent inhibition of HL-60 cell proliferation (Figure Sb) which was much greater than the inhibition induced by free phosphorothioate ODNs ( Figure Sa) . Moreover, the proliferation rate of HL-60 cells exposed to the FA-polylysine-sense ODN complex was unaffected ( Figure Sb) . To determine whether the marked c-myb mRNA was barely detectable in cells treated with the FA-polylysine-c-myb antisense ODN complex, while it was highly expressed in sense-treated and control cells ( Figure 6 ). Densitometric measurement of the c-myb hybridising band in sense-vs-antisense oligodeoxynucleotide-treated samples indicated that the signal from the antisense-treated samples was <5% of that from the sense-treated samples.
Discussion
In this study we present a protocol for the synthesis and purification of a covalent conjugate of FA and polylysine Figure 6 The expression of c-myb mRNA in HL-60 cells chain ( Figure 1 ) to be employed as vehicle for ODNs. As shown in Figure 2 the covalent coupling of a polylysine chain to FA did not prevent the ligand being recognised by specific monoclonal antibodies, suggesting that FA maintained its biological activity. Other authors also provide evidence to support this hypothesis (Leamon & Low, 1991 (Figure 3) . The fluorescence microscopy results (Figure 4) clearly indicate that the conjugate interacts with the cell membrane after a few minutes and then enters the cells. Therefore, as this process can be competitively blocked by free folate, it would appear that the cells are capable of internalising folate conjugates through a folate receptor-mediated mechanism (Barton & Capdevila, 1986) . The non-lysosomal pathway internalisation of folate into the cells (Rothemberg et al., 1990; Asok, 1992; Weitman et al., 1992) (Farber et al., 1975; Stein & Cheng, 1993) . As with the delivery system based on the use of a transferrin-polylysine complex (Citro et al., 1992; Manfredini et al., 1993) , the system described here represents a useful means of targeting and of intracellular uptake of ODNs into tumour cells. Furthermore, this study also shows that the FA-polylysine c-myb antisense complex, unlike FA-polylysine c-myb sense, specifically reduces the c-myb mRNA level in treated cells (Figure 6 ).
Taking into account the receptor expression on the tumour cell membranes, two or more vehicles carrying antisense ODNs directed against the encoded mRNAs can be made. The ideal surface receptors to exploit for a selective delivery of antisense ODNs would undoubtedly be those exclusively expressed by tumour cells. Alternatively, receptors which are overexpressed in some neoplastic cells, such as the EGF, the transferrin (Klausner et al., 1983; Simons et al., 1992) and the FA receptors (Klausner et al., 1983; Kamen et al., 1988; Hopkins et al., 1990; Asok, 1992; Simons et al., 1992; Weitman et al., 1992; Berczi et al., 1993) , could also be used.
Recent results (Ratajczak et al., 1993; T. Skorski et al., 1994) indicate that anti-oncogene-targeted phosphorothioate ODNs administered in vivo possess antitumoral activity against tumour cells, resulting in an increase in animal survival. Yet a relative paucity of phosphorothioate vs phosphodiester successes in tissue culture when targeted to mammalian mRNAs has also been reported (Stein & Cheng, 1993) . Consequently, complexed phosphodiester ODNs should perhaps be considered as their metabolites are less toxic to the cells. However, as with any other drug in the developmental process, further studies are required to assess the potential role of antisense oligodeoxynucleotides in therapeutic applications. This work was supported by grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC); CNR PF ACRO (No. 92.02370.P.F.39); NIH and ACS. B.C. is a scholar of the Leukemia Society of America.
